Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Breast Cancer

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

The Phase 1/2 asset targets PIK3CA‑mutant tumors to improve tolerability in HR+/HER2‑ breast cancer with closing expected in the first half of 2026.

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy